We are live on ! Find out more
OTLK icon

Outlook Therapeutics

76 hedge funds and large institutions have $29.8M invested in Outlook Therapeutics in 2022 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 25 increasing their positions, 19 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

428% more capital inflows, than outflows

Capital inflows: $4.61M | Capital outflows: $874K

32% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 19

1.53% more ownership

Funds ownership: 10.66% → 12.19% (+1.5%)

0% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 9

1% less funds holding

Funds holding: 77 → 76 (-1)

Holders
76
Holders Change
-1
Holders Change %
-1.3%
% of All Funds
1.22%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
9
Increased
25
Reduced
19
Closed
9
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

OTLK Hedge Fund Activity: Q4 2022 in Review

76 of the 6,245 institutional investors tracked by Wall St. Rank reported a position in Outlook Therapeutics (OTLK) for Q4 2022, worth a combined $29.8M — up 1.2% from $29.4M a quarter earlier.

Fund positioning in OTLK was balanced in Q4 2022: 9 funds opened new positions, 9 closed out, 25 added to existing stakes and 19 trimmed.

The largest buyer was Altium Capital Management, opening a new position worth an estimated $3.62M. The largest seller was Fidelity Investments, cutting an estimated $164K.

  • 76 institutional investors held Outlook Therapeutics (OTLK) as of Q4 2022, down from 77 in Q3 2022.
  • Funds reported $29.8M of Outlook Therapeutics stock for Q4 2022, up 1.2% quarter-over-quarter.
  • 9 funds opened new Outlook Therapeutics positions in Q4 2022 and 9 closed out, a net change of 0 holders.
  • The largest Outlook Therapeutics buyer in Q4 2022 was Altium Capital Management, an estimated $3.62M added.
  • The largest Outlook Therapeutics seller in Q4 2022 was Fidelity Investments, an estimated $164K sold.

Based on aggregated 13F filings for Q4 2022.